Clinical Trial Detail

NCT ID NCT02574663
Title TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

gastroesophageal junction adenocarcinoma

colorectal adenocarcinoma

pancreatic adenocarcinoma

gastric adenocarcinoma

gastrointestinal stromal tumor

Therapies

Gemcitabine + Nab-paclitaxel

Bevacizumab

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Umbralisib

Age Groups: adult

No variant requirements are available.